Supraventricular tachycardia AHA recommendations for Management of IST: Difference between revisions
Aysha Aslam (talk | contribs) (Created page with "__NOTOC__ {{Supraventricular tachycardia}} {{CMG}} {{AE}}{{AA}} ==Overview== ==Management of IST== ==References== {{Reflist|2}}") |
Aysha Aslam (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Management of IST== | ==Management of IST== | ||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Evaluation for and treatment of reversible causes are recommended in patients with suspected IST <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Ivabradine is reasonable for ongoing management in patients with symptomatic IST <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Beta blockers may be considered for ongoing management in patients with symptomatic IST <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C-LD]])'' <nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.'''The combination of beta blockers and ivabradine may be considered for ongoing management in patients with IST ( <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | |||
|- | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 19:31, 25 October 2016
|
Supraventricular tachycardia Microchapters |
|
Differentiating Among the Different Types of Supraventricular Tachycardia |
|---|
|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
|
Diagnosis |
|
Treatment |
|
2015 ACC/AHA Guideline Recommendations |
|
Case Studies |
|
Supraventricular tachycardia AHA recommendations for Management of IST On the Web |
|
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of IST |
|
FDA on Supraventricular tachycardia AHA recommendations for Management of IST |
|
CDC on Supraventricular tachycardia AHA recommendations for Management of IST |
|
Supraventricular tachycardia AHA recommendations for Management of IST in the news |
|
Blogs on Supraventricular tachycardia AHA recommendations for Management of IST |
|
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Management of IST
| Class I |
| "1.Evaluation for and treatment of reversible causes are recommended in patients with suspected IST "(Level of Evidence: C-LD) " |
| Class IIa |
| "1.Ivabradine is reasonable for ongoing management in patients with symptomatic IST "(Level of Evidence: B-R) " |
| Class IIb |
| "1.Beta blockers may be considered for ongoing management in patients with symptomatic IST "(Level of Evidence:C-LD) " |
| "2.The combination of beta blockers and ivabradine may be considered for ongoing management in patients with IST ( "(Level of Evidence: C-LD) " |